|
[1]
|
Heidenreich, P.A., et al. (2022) Correction to: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145, e1033. [Google Scholar] [CrossRef]
|
|
[2]
|
Markham, A. and Duggan, S. (2021) Vericiguat: First Approval. Drugs, 81, 721-726. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Armstrong, P.W., et al. (2020) Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. The New England Journal of Medicine, 382, 1883-1893. [Google Scholar] [CrossRef]
|
|
[4]
|
Lombardi, C.M., et al. (2021) Vericiguat for Heart Failure with Re-duced Ejection Fraction. Current Cardiology Reports, 23, Article No. 144. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Armstrong, P.W., et al. (2020) Effect of Vericiguat vs Placebo on Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. JAMA, 324, 1512-1521. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Diana Bonderman, et al. (2013) Riociguat for Patients with Pulmo-nary Hypertension Caused by Systolic Left Ventricular Dysfunction: A Phase IIb Double-Blind, Randomized, Place-bo-Controlled, Dose-Ranging Hemodynamic Study. Circulation, 128, 502-511. [Google Scholar] [CrossRef]
|
|
[7]
|
Gheorghiade, M., et al. (2015) Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients with Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. JAMA, 314, 2251-2262.
https://jamanetwork.com/journals/jama/article-abstract/2469195
|
|
[8]
|
Pieske, B., et al. (2017) Vericiguat in Patients with Worsening Chronic Heart Failure and Preserved Ejection Fraction: Results of the Soluble Guanylate Cyclase Stimu-lator in Heart Failure Patients with PRESERVED EF (SOCRATES- PRESERVED) Study. European Heart Journal, 38, 1119-1127. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Gheorghiade, M., et al. (2013) Soluble Guanylate Cyclase: A Potential Therapeutic Target for Heart Failure. Heart Failure Reviews, 18, 123-134. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Follmann, M., et al. (2017) Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure. Journal of Medicinal Chem-istry, 60, 12, 5146-5161. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Buys, E.S., et al. (2008) Gender-Specific Hypertension and Responsiveness to Nitric Oxide in sGCa1 Knockout Mice. Cardiovascular Research, 79, 179-186.
|
|
[12]
|
Ky, B., et al. (2013) Ventricular-Arterial Coupling, Remodeling, and Prognosis in Chronic Heart Failure. Journal of the American College of Cardiology, 62, 1165-1172. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Schmidt, H.H.H.W., Schmidt, P.M. and Stasch, J.P. (2009) NO- and Haem-Independent Soluble Guanylate Cyclase Activators. In: Schmidt, H.H.H.W., Hofmann, F. and Stasch, J.P., Eds., cGMP: Generators, Effectors and Therapeutic Implications, Springer, Berlin, 309-339. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Evgenov, O.V., Pacher, P., Schmidt, P.M., Haskó, G. and Stasch, J.P. (2008) NO-Independent Stimulators and Activators of Soluble Guanylate Cyclase: Discovery and Therapeutic Potential. Nature Reviews Drug Discovery, 5, 755-768.
|
|
[15]
|
Sharkovska, Y., et al. (2010) Nitric Ox-ide-Independent Stimulation of Soluble Guanylate Cyclase Reduces Organ Damage in Experimental Low-Renin and High-Renin Models. Journal of Hypertension, 28, 1666-1675. [Google Scholar] [CrossRef]
|
|
[16]
|
Shaikh, T.G., et al. (2023) Efficacy and Safety of Vericiguat for Treatment of Heart Failure: A Systematic Review. Current Problems in Cardiology, 48, Article ID: 101586. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Tan, Y.T., et al. (2009) The Pathophysiology of Heart Failure with Normal Ejection Fraction: Exercise Echocardiography Reveals Complex Abnormalities of Both Systolic and Dias-tolic Ventricular Function Involving Torsion, Untwist, and Longitudinal Motion. Journal of the American College of Cardiology, 54, 36-46.
|
|
[18]
|
Lou, Q., et al. (2023) Vericiguat Reduces Electrical and Structural Remodeling in a Rabbit Model of Atrial Fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics, 28, 9. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Lam, C.S.P., et al. (2009) Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction: A Community-Based Study. Journal of the American College of Cardiology, 53, 1119-1126. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Leung, C.C., Moondra, V., Catherwood, E. and Andrus, B.W. (2010) Prevalence and Risk Factors of Pulmonary Hypertension in Patients with Elevated Pulmonary Venous Pressure and Preserved Ejection Fraction. American Journal of Cardiology, 106, 284-286.
https://www.ajconline.org/article/S0002-9149(10)00703-4/fulltext
|
|
[21]
|
Ghofrani, H.A., et al. (2013) Riociguat for the Treatment of Pulmonary Arterial Hypertension. The New England Journal of Medicine, 369, 330-340. [Google Scholar] [CrossRef]
|
|
[22]
|
Hossein-Ardeschir Ghofran, et al. (2013) Riociguat for the Treat-ment of Chronic Thromboembolic Pulmonary Hypertension. The New England Journal of Medicine, 369, 319-329.
https://www.nejm.org/doi/10.1056/NEJMoa1209657
|
|
[23]
|
Rotariu, D., et al. (2022) Oxidative Stress—Complex Pathological Issues Concerning the Hallmark of Cardiovascular and Metabolic Disorders. Biomedicine & Pharma-cotherapy, 152, Article ID: 113238. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Liu, Y.N., et al. (2006) YC-1 [3-(5’-Hydroxymethyl-2’-Furyl)-1-Benzyl Indazole] Inhibits Neointima Formation in Balloon-Injured Rat Carotid through Suppression of Expressions and Activities of Matrix Metalloproteinases 2 and 9. Journal of Pharmacology and Experimental Therapeutics, 316, 35-41. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Grundy, S.M., et al. (2004) Definition of Metabolic Syndrome. Circulation, 109, 433-438.
https://www.ahajournals.org/doi/10.1161/01.CIR.0000111245.75752.C6?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
|
|
[26]
|
Schwartzkopf, C.D., et al. (2022) Beneficial Metabolic Effects of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in a Mouse Diet-Induced Obesity Model. Frontiers in Pharmacolo-gy, 13, Article ID: 852080. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Stasch, J.P., Schlossmann, J. and Hocher, B. (2015) Renal Effects of Soluble Guanylate Cyclase Stimulators and Activators: A Review of the Preclinical Evidence. Current Opinion in Pharmacology, 21, 95-104. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Ott, I.M., et al. (2012) Effects of Stimulation of Soluble Guanylate Cyclase on Diabetic Nephropathy in Diabetic eNOS Knockout Mice on Top of Angiotensin II Receptor Blockade. PLOS ONE, 7, e42623. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Xia, J., et al. (2022) Development of Vericiguat: The First Solu-ble Guanylate Cyclase (sGC) Stimulator Launched for Heart Failure with Reduced Ejection Fraction (HFrEF). Biomedi-cine & Pharmacotherapy, 149, Article ID: 112894. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Paulus, W.J. and Tschöpe, C. (2013) A Novel Paradigm for Heart Failure with Preserved Ejection Fraction. Journal of the American College of Cardiology, 62, 263-271. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Tobin, J.V., et al. (2018) Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, An-ti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease. Journal of Pharmacology and Experimental Therapeutics, 365, 664-675. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Boettcher, M., et al. (2021) Safety, Pharmacodynamic, and Pharma-cokinetic Characterization of Vericiguat: Results from Six Phase I Studies in Healthy Subjects. European Journal of Clinical Pharmacology, 77, 527-537. [Google Scholar] [CrossRef] [PubMed]
|